This NDC is on FDA's drug shortage list (posted Jul 14, 2023)
Product Information
VYVANSE 70 MG CAPSULE is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $12.3520 per EA under NDC 59417010710. Its NADAC has been published 665 times since Nov 28, 2013.
FDA first approved this application on Feb 23, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the lisdexamfetamine dimesylate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
70 mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
59417010710
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
LISDEXAMFETAMINE DIMESYLATEApproval Type
New Drug (NDA)
FDA Application
NDA021977FDA Approved
2/23/2007
TE Code
AB
On Market Since
2/23/2007
Pharmacological Classes
Price Statistics
The NADAC for VYVANSE 70 MG CAPSULE has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 106.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.3520 per EA |
|---|---|
| All-time high | $12.3886 (Sep 11, 2024) |
| All-time low | $5.9862 (Nov 28, 2013) |
| 52-week high | $12.3736 |
| 52-week low | $12.3520 |
| Median price | $10.2007 |
| Average price | $9.9445 |
| Largest weekly change | +9.0% (Jan 8, 2014) |
| Weeks tracked | 665 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 78% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of VYVANSE 70 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for VYVANSE 70 MG CAPSULE, manufactured by Takeda Pharmaceuticals America, Inc., is $12.3520 per EA (NDC 59417010710), effective Aug 19, 2026.
How has the price of VYVANSE 70 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for VYVANSE 70 MG CAPSULE has risen 106.3%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for VYVANSE 70 MG CAPSULE?
Since Nov 28, 2013, the NADAC for VYVANSE 70 MG CAPSULE has ranged from a low of $5.9862 (Nov 28, 2013) to a high of $12.3886 (Sep 11, 2024), with a median of $10.2007 per EA.
Are there cheaper alternatives to VYVANSE 70 MG CAPSULE?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LISDEXAMFETAMINE 70 MG CAPSULE, is $2.7593 per EA — about 78% below VYVANSE 70 MG CAPSULE.
Who manufactures VYVANSE 70 MG CAPSULE?
VYVANSE 70 MG CAPSULE (NDC 59417010710) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.
Is VYVANSE 70 MG CAPSULE in shortage?
Yes — NDC 59417010710 is currently listed in FDA's drug shortage database (posted Jul 14, 2023).